GlassScriptPhysician profile
Matthew C Winkleman
NPI 1225018153
$2,112.30
in general payments reported to CMS, 2019-2025
24 companies · $888 in 2025
The $888 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.26 · 2022: $67.87 · 2023: $167 · 2024: $963 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.84 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $323.44 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $319.07 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $157.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $140.98 | 2023-2025 | |
| Dexcom, INC. | $113.42 | 2022-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $81.99 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $79.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $74.51 | 2023-2024 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $56.51 | 2024 | |
| Phathom Pharmaceuticals, INC. | $50.78 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $42.58 | 2024-2025 | Gemtesa |
| Verona Pharma, INC. | $34.47 | 2025 | Ohtuvayre |
| Abbott Laboratories | $30.71 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $29.28 | 2024 | Camzyos, Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.07 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $21.54 | 2024 | Keveyis |
| Mylan Specialty L.P. | $21.36 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $19.65 | 2024 | Xarelto |
| Exact Sciences Corporation | $16.81 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.25 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $15.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2023 | Jardiance, Tradjenta |
| Aimmune Therapeutics, INC. | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Winkleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.